Skip to search formSkip to main contentSkip to account menu

Serine/Threonine Kinase Inhibitor CBP501

A peptide with G2 checkpoint-abrogating activity. G2 checkpoint inhibitor CBP501 inhibits multiple serine/threonine kinases, including MAPKAP-K2, C… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
CBP501 is an anticancer drug candidate that was investigated in two randomized phase II clinical trials for patients with…